Researchers have found that an antibody -- originally developed for studying the autoimmune condition multiple sclerosis -- can promote the immune system's ability to fight cancer and decreases tumour growth. In a study published in the journal Science Immunology the researchers reported that the antibody decreased tumour growth in models of melanoma (skin cancer) glioblastoma (brain cancer) and colorectal carcinoma making it an attractive candidate for cancer immunotherapy. The antibody can precisely target regulatory T cells which in turn unleash the immune system to kill cancer cells. T cells (Tregs) which help maintain the immune system's tolerance of self can
